Article Text

Ten-year cardiovascular risk in the general public of Hong Kong
  1. Vivian W Y Lee,
  2. Sally L T Law
  1. School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
  1. Correspondence to Professor Vivian W Y Lee, School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; vivianlee{at}


Background Coronary heart disease (CHD) is a major health issue in Hong Kong and has become the second leading cause of death since the 1960s. The prevalence of CHD and its mortality in Hong Kong are approaching a level that requires focused attention. Unfortunately, CHD could be a silent disease until the manifestations occur. Early detection and control of cardiovascular risk factors including cholesterol and blood pressure are vital.

Objective The current project aimed to investigate the 10-year cardiovascular risk in the general public of Hong Kong.

Design A 12-month prospective cross-sectional study.

Setting and patients General public of Hong Kong between April 2007 and April 2008.

Intervention Public screening of lipid panels and blood pressure.

Main outcome measurement Estimation of 10-year cardiovascular risk.

Results During this period, a total of 2607 patients were recruited with a mean age of 46.4±11.1 years (51.3% male), and 8.1% of subjects were active smokers. Among all of the subjects, the mean total cholesterol was 5.42±1.28 mmol/l, and the mean high density cholesterol was 1.59±0.75 mmol/l. The mean systolic blood pressure was 121.7±19.5 mm Hg. The assessment of the 10-year cardiovascular risk showed that 13.8% of the subjects were moderately high to high-risk patients.

Conclusion The general public in Hong Kong had a relatively high total cholesterol and normal-high systolic blood pressure. Almost two in every 10 Hong Kong citizens may have a 10–20% or more than 20% risk of developing CHD in the next 10 years.

  • Cardiovascular risk
  • public health
  • coronary heart disease
  • lipid lowering
  • public health
  • systolic heart failure

Statistics from


  • Funding This study was supported by the School of Pharmacy, The Chinese University of Hong Kong and Pfizer (HK) Corporation.

  • Competing interests None.

  • Ethics approval This is a public-health screening procedure.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.